The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2018 | MPN updates: personalized prognostication, novel treatments & more

Name: MPN updates: personalized prognostication, novel treatments & more
Uploaded: 2019-01-18T17:18:11.000Z
Duration: 2 min 38 s
Description: Ruben Mesa, MD, of the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, shares his view on the highlights for myeloproliferative neoplasms (MPNs), including novel treatments, outlooks, and individualized prognostication, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Ruben Mesa • 18 Jan 2019

ASH 2018

Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Azacitidine Decitabine Fedratinib Imetelstat Momelotinib Pacritinib Peginterferon alfa-2a PRM-151 Ruxolitinib Thalidomide

Ruben Mesa, MD, of the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, shares his view on the highlights for myeloproliferative neoplasms (MPNs), including novel treatments, outlooks, and individualized prognostication, from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.